American College of Cardiology 71st Scientific Sessions: Science Preview, April 3, 2022

Slideshow
Conference|ACC

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

Late-breaking ACC science on Sunday, April 2, begins at a session jointly sponsored by the ACC and the Journal of the American Medical Association, followed by the joint ACC/New England Journal of Medicine session and a second day of featured clinical research.

Look for studies on icosapent ethyl, vupanorsen, and alirocumab for hypercholesterolemia; for landmark research on HFrEF and on a novel FX1a inhibitor for treatment of atrial fibrillation.

Saturday, April 2, 2022 Late Breaking Clincial Trials

Monday, April 4, 2022 Late Breaking Clinical Trials

More News from ACC on Patient Care

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Investigational Drug Reduces Lp(a) in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Drug Reduces Lp(a) in High-Risk Adults: Daily Dose

Sydney Jennings
December 4th 2024
Article

Your daily dose of the clinical news you may have missed.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke / image credit American Heart Association

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Grace Halsey
November 11th 2024
Article

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Progression of Subclinical Atherosclerosis Independently Predicts All-Cause Mortality / image credit - plaque: ©Tefi/stock.adobe.com

Progression of Subclinical Atherosclerosis Independently Predicts All-Cause Mortality

Grace Halsey
October 2nd 2024
Article

The use of visual imaging to detect atherosclerosis at its earliest stages and to quantify the burden enhances predictive value of traditional risk assessment tools.

Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose / image credit: ©New Africa/AdobeStock

Recent Recreational Drug Use Ups Risk of Repeat Serious CV Event: Daily Dose

Sydney Jennings
September 18th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.